FDA authorizes emergency use of rapid response COVID-19 test
![FDA product update](/sites/default/files/styles/900x400/public/2018-04/FDA%20product%20update.jpg?itok=TkhlK6rs)
The Food and Drug Administration Friday authorized emergency use of the ID NOW Instrument in patient care settings to quickly test for COVID-19 through direct nasal or throat swab testing. According to the manufacturer, Abbott, the test may detect positive results in five minutes and negative results in 13 minutes. Read the authorization letter and health care provider factsheet here.
Related News Articles
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…
Headline
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…
Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…